Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Guilan Shi"'
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 2, Pp 194-204 (2022)
Abstract. Background:. Despite improvements in disease diagnosis, treatment, and prognosis, breast cancer is still a leading cause of cancer death for women. Compelling evidence suggests that targeting cancer stem cells (CSCs) have a crucial impact o
Externí odkaz:
https://doaj.org/article/01c91b3785944568a2f506f66e017f14
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2429 (2022)
Resistance to checkpoint-blockade treatments is a challenge in the clinic. Both primary and acquired resistance have become major obstacles, greatly limiting the long-lasting effects and wide application of blockade therapy. Many patients with metast
Externí odkaz:
https://doaj.org/article/0df6f67178d44c13bb3f8f5b4648fb07
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Pediatric-onset systemic lupus erythematosus arises in humans and mice lacking the endonuclease Dnase1L3. When Dnase1L3 is absent, DNA from circulating apoptotic bodies is not cleared, leading to anti-DNA antibody production. Compared to early anti-D
Externí odkaz:
https://doaj.org/article/20feb420332541978448e6899f123198
Publikováno v:
Chinese Medical Journal
Chinese Medical Journal, Vol 135, Iss 2, Pp 194-204 (2022)
Chinese Medical Journal, Vol 135, Iss 2, Pp 194-204 (2022)
Background:. Despite improvements in disease diagnosis, treatment, and prognosis, breast cancer is still a leading cause of cancer death for women. Compelling evidence suggests that targeting cancer stem cells (CSCs) have a crucial impact on overcomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5a5ab6dfbe1594e75c096863d650e69
http://europepmc.org/articles/PMC8769120
http://europepmc.org/articles/PMC8769120
Autor:
Heller Richard, Guilan Shi
Publikováno v:
Dermatology and Dermatitis. 4:01-04
Melanoma mortality rates are the highest amongst skin cancer patients. The 5-year survival rate is 92% if melanoma is diagnosed at an early stage and is localized. If melanoma has spread to other parts of the body, survival is only 13%. Therefore, it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35a0ea2381abb9d9f181e0d2167bcfcb
https://doi.org/10.31579/2578-8949/052
https://doi.org/10.31579/2578-8949/052
Autor:
Guilan, Shi, Richard, Heller
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2265
Within the adaptive and innate immune system, effector lymphocytes known as cytotoxic T cells (CTLs) or natural killer (NK) cells play an essential role in host defense against tumor cells and virally infected cells. Here we describe a flow cytometry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::792b6ecdb0a6b0ee5f84c98e263ea47f
https://pubmed.ncbi.nlm.nih.gov/33704709
https://pubmed.ncbi.nlm.nih.gov/33704709
Autor:
Richard, Heller, Guilan, Shi
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2265
Gene electrotransfer (GET) is a reliable and effective physical method for in vivo delivery of plasmid DNA (pDNA). Several preclinical and clinical studies have utilized GET to deliver plasmids encoding immune stimulating genes for treatment of melan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::633c7a1e388643f8ad3e8b59154de4a0
https://pubmed.ncbi.nlm.nih.gov/33704744
https://pubmed.ncbi.nlm.nih.gov/33704744
Publikováno v:
Cancer Research. 82:3289-3289
Immune checkpoint inhibitors (ICIs) such as PD-1 targeting antibodies nivolumab and pembrolizumab are FDA approved as therapies for many cancers. These ICIs inhibit PD-1 ligand binding, removing interference with T cell function, allowing T cell prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca9652fc04dea4bc5c8e48df28c38c10
https://doi.org/10.1158/1538-7445.am2022-3289
https://doi.org/10.1158/1538-7445.am2022-3289
Publikováno v:
Cancer Research. 82:4210-4210
Immune checkpoint inhibitors (ICIs) have been demonstrated to have significant clinical benefits. Effectiveness of ICIs have been limited by both primary and acquired resistance. In addition, absence of T cell infiltration within the tumor site is on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9df61cac19af5d3757102c3a5eaa1bfc
https://doi.org/10.1158/1538-7445.am2022-4210
https://doi.org/10.1158/1538-7445.am2022-4210
Autor:
Guilan Shi, Richard Heller
Publikováno v:
The Journal of Immunology. 208:118.02-118.02
Background Immune checkpoint inhibition (ICI) has led to impressive gains in survival for many patients. However, many cancer patients treated with ICI experience intrinsic or acquired resistance which directly affects efficacy. Decreased levels of M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f8408f555dcfa7fae600579a44a27a1
https://doi.org/10.4049/jimmunol.208.supp.118.02
https://doi.org/10.4049/jimmunol.208.supp.118.02